Development Progress-Humanwell Healthcare (Group) Co.-Humanwell Healthcare (Group) Co.

Development Progress

CURRENT LOCATION: HOME > R&D and Innovation > Development Progress

Overview

R&D Centers

Development Progress

Technology Platform

Introduction To Key Projects

Development Progress

R&D Projects	Registration Category	Indication/Therapeutic Use	Phase I	Phase II	Phase III	Approved

PUDK-HGF	Biological Products Category 1	Rest pain and/or ischemic ulcers in limbs due to severe ischemic disease of the lower extremities
Remazolam Besylate for Injection New Indication	Chemical category 1	Sedation during intensive care unit (ICU)
PARP Inhibitors	Chemical category 1	Ovarian cancer, breast cancer, lung cancer, etc
BTK Inhibitors	Chemical category 1	Chronic spontaneous urticaria
HW021199 Tablets	Chemical category 1	Treatment of idiopathic pulmonary fibrosis
RFUS-144 Injection	Chemical category 1	Treatment of pain and pruritus
Bai-re-si Pills	Chemical category 1	Treatment of stable vitiligo
Compound Yixie Granules	Chemical category 1	Hyperuricemia in the non-acute phase of gout and syndrome of stasis of dampness and turbidness
LL-50 Injection	Chemical category 1	Control of surgical anesthesia and acute pain
HW060015 Capsules	Chemical category 1	Patients with advanced solid tumors
HW091077 Tablets	Chemical category 1	Patients with refractory chronic cough
YJJS-71	Chemical category 1	New skeletal muscle relaxation drug
RF16001 for Injection	Chemical category 2	Postoperative analgesia
Sufentanil Transdermal Patch	Chemical category 2	Treatment of moderate to severe chronic pain
Oxycodone and Acetaminophen Extended-release Tablets	Chemical category 2	Analgesia of moderate to severe neuralgia
Tapentadol Hydrochloride Preparations	Chemical category 3	Relief of moderate to severe pain in adults of 18 years of age and older; treatment of pain that requires long-term treatment with opioid analgesics
Fentanyl Citrate Oral Patch	Chemical category 3	For the treatment of explosive pain in patients with cancerous pain who have been using opioids continuously
Methylnaltrexone Bromide Preparations	Chemical category 3	For the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancerous pain

CURRENT LOCATION:

HOME > R&D and Innovation> Development Progress

Group Subsidiary GROUP SUBSIDIARY

Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.

QRCode

COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

Privacy protection Legal statement

Technical Support: Lucky xp